US 11,951,212 B2
Pharmaceutical compositions for the treatment of cystic fibrosis transmembrane conductance regulator mediated diseases
Brian Dean Phenix, Acton, MA (US); Laurent Jean-Claude Bagnol, Burlington, MA (US); Geoffrey Glen Brodeur, Somerville, MA (US); Sachin Chandran, Somerville, MA (US); Eleni Dokou, Cambridge, MA (US); Lori Ann Ferris, Medford, MA (US); Dragutin Knezic, Watertown, MA (US); Katie Lynn McCarty, Watertown, MA (US); Ales Medek, Winchester, MA (US); and Sara A. Waggener, N. Billerica, MA (US)
Assigned to Vertex Pharmaceuticals Incorporated, Boston, MA (US)
Filed by Vertex Pharmaceuticals Incorporated, Boston, MA (US)
Filed on Mar. 17, 2021, as Appl. No. 17/204,679.
Application 17/204,679 is a continuation of application No. 16/232,540, filed on Dec. 26, 2018, granted, now 10,980,746.
Application 16/232,540 is a continuation of application No. 14/686,117, filed on Apr. 14, 2015, granted, now 10,206,877, issued on Feb. 19, 2019.
Claims priority of provisional application 62/059,287, filed on Oct. 3, 2014.
Claims priority of provisional application 61/979,848, filed on Apr. 15, 2014.
Prior Publication US 2021/0308053 A1, Oct. 7, 2021
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 31/404 (2006.01); A61K 9/14 (2006.01); A61K 9/16 (2006.01); A61K 9/20 (2006.01); A61K 31/443 (2006.01); A61K 31/47 (2006.01); A61K 31/4709 (2006.01); A61K 31/4725 (2006.01); A61K 45/06 (2006.01); C07D 209/04 (2006.01); C07D 215/00 (2006.01); C07D 215/56 (2006.01); C07D 405/12 (2006.01)
CPC A61K 9/14 (2013.01) [A61K 9/146 (2013.01); A61K 9/16 (2013.01); A61K 9/1652 (2013.01); A61K 9/2054 (2013.01); A61K 9/2077 (2013.01); A61K 31/404 (2013.01); A61K 31/443 (2013.01); A61K 31/47 (2013.01); A61K 31/4709 (2013.01); A61K 31/4725 (2013.01); A61K 45/06 (2013.01); C07D 209/04 (2013.01); C07D 215/00 (2013.01); C07D 215/56 (2013.01); C07D 405/12 (2013.01)] 37 Claims
 
1. A pharmaceutical composition comprising a blend of a first solid dispersion and a second solid dispersion,
wherein the first solid dispersion comprises 70 wt % to 90 wt % of amorphous (R)-1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl)-N-(1-(2,3-dihydroxypropyl)-6-fluoro-2-(1-hydroxy-2-methylpropan-2-yl)-1H-indol-5-yl)cyclopropanecarboxamide (Compound 1) relative to the total weight of the first solid dispersion and 10 wt % to 30 wt % of a polymer relative to the total weight of the first solid dispersion,
wherein the second solid dispersion comprises 70 wt % to 90 wt % of amorphous N-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide (Compound 2) relative to the total weight of the second solid dispersion; and
wherein the pharmaceutical composition is a tablet that comprises 25 mg to 125 mg of Compound 1 and 100 mg to 200 mg of Compound 2.